vs

Side-by-side financial comparison of Goosehead Insurance, Inc. (GSHD) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Goosehead Insurance, Inc. is the larger business by last-quarter revenue ($93.1M vs $74.7M, roughly 1.2× Health Catalyst, Inc.). Goosehead Insurance, Inc. runs the higher net margin — 8.6% vs -121.9%, a 130.5% gap on every dollar of revenue. On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs -6.2%). Over the past eight quarters, Goosehead Insurance, Inc.'s revenue compounded faster (9.2% CAGR vs -0.0%).

Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

GSHD vs HCAT — Head-to-Head

Bigger by revenue
GSHD
GSHD
1.2× larger
GSHD
$93.1M
$74.7M
HCAT
Growing faster (revenue YoY)
GSHD
GSHD
+29.3% gap
GSHD
23.1%
-6.2%
HCAT
Higher net margin
GSHD
GSHD
130.5% more per $
GSHD
8.6%
-121.9%
HCAT
Faster 2-yr revenue CAGR
GSHD
GSHD
Annualised
GSHD
9.2%
-0.0%
HCAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
GSHD
GSHD
HCAT
HCAT
Revenue
$93.1M
$74.7M
Net Profit
$8.0M
$-91.0M
Gross Margin
Operating Margin
16.1%
-115.3%
Net Margin
8.6%
-121.9%
Revenue YoY
23.1%
-6.2%
Net Profit YoY
204.0%
-340.3%
EPS (diluted)
$0.19
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GSHD
GSHD
HCAT
HCAT
Q1 26
$93.1M
Q4 25
$105.3M
$74.7M
Q3 25
$90.4M
$76.3M
Q2 25
$94.0M
$80.7M
Q1 25
$75.6M
$79.4M
Q4 24
$93.9M
$79.6M
Q3 24
$78.0M
$76.4M
Q2 24
$78.1M
$75.9M
Net Profit
GSHD
GSHD
HCAT
HCAT
Q1 26
$8.0M
Q4 25
$12.4M
$-91.0M
Q3 25
$7.9M
$-22.2M
Q2 25
$5.2M
$-41.0M
Q1 25
$2.3M
$-23.7M
Q4 24
$14.9M
$-20.7M
Q3 24
$7.6M
$-14.7M
Q2 24
$6.2M
$-13.5M
Gross Margin
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Operating Margin
GSHD
GSHD
HCAT
HCAT
Q1 26
16.1%
Q4 25
29.4%
-115.3%
Q3 25
23.5%
-22.9%
Q2 25
16.7%
-46.0%
Q1 25
8.8%
-25.4%
Q4 24
29.7%
-22.0%
Q3 24
21.1%
-17.9%
Q2 24
19.7%
-20.8%
Net Margin
GSHD
GSHD
HCAT
HCAT
Q1 26
8.6%
Q4 25
11.8%
-121.9%
Q3 25
8.7%
-29.1%
Q2 25
5.5%
-50.8%
Q1 25
3.1%
-29.9%
Q4 24
15.8%
-26.0%
Q3 24
9.7%
-19.3%
Q2 24
7.9%
-17.8%
EPS (diluted)
GSHD
GSHD
HCAT
HCAT
Q1 26
$0.19
Q4 25
$0.48
$-1.29
Q3 25
$0.29
$-0.32
Q2 25
$0.18
$-0.59
Q1 25
$0.09
$-0.35
Q4 24
$0.58
$-0.33
Q3 24
$0.29
$-0.24
Q2 24
$0.24
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GSHD
GSHD
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$25.7M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$-121.3M
$245.8M
Total Assets
$392.8M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GSHD
GSHD
HCAT
HCAT
Q1 26
$25.7M
Q4 25
$34.4M
$95.7M
Q3 25
$51.6M
$91.5M
Q2 25
$92.4M
$97.3M
Q1 25
$70.2M
$342.0M
Q4 24
$54.3M
$392.0M
Q3 24
$47.5M
$387.3M
Q2 24
$23.6M
$308.3M
Total Debt
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
$289.5M
$153.3M
Q3 25
$290.0M
$153.1M
Q2 25
$289.8M
$153.0M
Q1 25
$290.3M
$382.9M
Q4 24
$82.3M
$382.4M
Q3 24
$84.6M
$345.0M
Q2 24
$87.0M
Stockholders' Equity
GSHD
GSHD
HCAT
HCAT
Q1 26
$-121.3M
Q4 25
$-95.5M
$245.8M
Q3 25
$-105.0M
$331.9M
Q2 25
$-78.6M
$347.5M
Q1 25
$-88.5M
$376.8M
Q4 24
$43.9M
$365.2M
Q3 24
$58.3M
$355.0M
Q2 24
$39.8M
$357.0M
Total Assets
GSHD
GSHD
HCAT
HCAT
Q1 26
$392.8M
Q4 25
$414.9M
$502.6M
Q3 25
$403.6M
$587.1M
Q2 25
$436.6M
$616.2M
Q1 25
$412.6M
$891.5M
Q4 24
$397.7M
$858.9M
Q3 24
$358.1M
$813.0M
Q2 24
$338.2M
$691.7M
Debt / Equity
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.87×
1.05×
Q3 24
1.45×
0.97×
Q2 24
2.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GSHD
GSHD
HCAT
HCAT
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
$91.8M
$9.9M
Q3 25
$24.2M
$-464.0K
Q2 25
$28.9M
$-9.0M
Q1 25
$15.5M
$280.0K
Q4 24
$71.5M
$-3.5M
Q3 24
$28.1M
$6.2M
Q2 24
$18.9M
$1.6M
Free Cash Flow
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
$86.1M
$9.6M
Q3 25
$23.7M
$-719.0K
Q2 25
$27.2M
$-9.2M
Q1 25
$14.9M
$-390.0K
Q4 24
$70.6M
$-3.9M
Q3 24
$28.0M
$5.5M
Q2 24
$18.6M
$1.3M
FCF Margin
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
81.8%
12.9%
Q3 25
26.2%
-0.9%
Q2 25
28.9%
-11.4%
Q1 25
19.7%
-0.5%
Q4 24
75.1%
-4.9%
Q3 24
35.9%
7.2%
Q2 24
23.9%
1.7%
Capex Intensity
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
5.4%
0.4%
Q3 25
0.5%
0.3%
Q2 25
1.8%
0.3%
Q1 25
0.8%
0.8%
Q4 24
1.0%
0.5%
Q3 24
0.1%
0.9%
Q2 24
0.3%
0.4%
Cash Conversion
GSHD
GSHD
HCAT
HCAT
Q1 26
Q4 25
7.38×
Q3 25
3.06×
Q2 25
5.61×
Q1 25
6.61×
Q4 24
4.82×
Q3 24
3.72×
Q2 24
3.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GSHD
GSHD

Renewal Royalty Fees (2)$43.6M47%
Renewal Commissions (1)$18.2M20%
Contingent Commissions (1)$10.7M11%
New Business Royalty Fees (2)$7.9M8%
New Business Commissions (1)$7.5M8%
Other$3.7M4%
Initial Franchise Fees (2)$1.6M2%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons